Flemingsberg Science Foundation Summer Party 2025 – What’s Happening in Flemingsberg?

What’s Happening in Flemingsberg?
There was a time when that question was rarely asked – but that time is long gone!

On Tuesday, June 10, 130 people gathered to celebrate the start of summer together. Business leaders, municipal and regional representatives, academia, and students came together under the theme “What’s Happening in Flemingsberg?” – an evening dedicated to sharing the latest developments: new establishments, initiatives, innovations, and future plans in Flemingsberg.

The stage was filled with optimism and forward-thinking. Representatives from Alfa Laval, Fabege, and Huddinge Municipality – among others – shared visions and concrete steps toward an even stronger Flemingsberg. In addition to inspiring conversations and great food, guests were treated to fantastic live music by students from the Stockholm University College of Music Education.

Flemingsberg is not a place you pass through – it’s a place on the move.
In Flemingsberg, we make everything possible.

A big thank you to our sponsor and associated partner Fabege!

Portabel Health: Crowned Winner of Flemingsberg Science STARTUP Award 2025

Quickly finding the right personnel is one of the healthcare sector’s major challenges, especially in times of staff shortages and increasing demands for efficiency. Portabel Health offers a modern solution to these problems through a digital platform that makes it easy for care providers to access qualified nurses and healthcare professionals.

Press Start: The Game Hub in Flemingsberg – Finally!

On April 24th, after just two months of hard work, it was finally time for the kick-off for the game cluster Press Start. The initiative is led by Drivhuset, in close collaboration with Flemingsberg Science Foundation and Södertörn University's Innovation Station.

AlzeCure Pharma – a hope in the fight against Alzheimer’s

Neurological diseases and the pain area are struggling with great medical needs, including the lack of broad-spectrum drugs. Those are gaps in the market that AlzeCure Pharma wants to fill, and they are well on their way. They recently received a grant from the European Innovation Council (EIC) to finance a clinical phase 2 study of the drug candidate NeuroRestore ACD856 for Alzheimer’s disease.

Previous 345 Next